Prognostic values of detecting MSI phenotypes in colorectal carcinoma by immunohistochemicalmethod compared to molecular investigation

##plugins.themes.academic_pro.article.sidebar##

Published May 14, 2018
Download
pdf
Vol. 95 No. 12 (2017): Issue Dec 2017

##plugins.themes.academic_pro.article.main##

Mona Trabelsi
Faten farah
Ahlem Blel
Departement of Pathology
Mohamed Habib Jaafoura
Maher Kharrat
Soumaya Rammeh

Abstract

Background:
The identification essentially of hMSH2 and/or hMLH1 alterations has clinical implications for recognition and prognosis of MSI phenotypes cases. In this study, we tried to identify instability by immunohistochemical expression pattern analysis, compared the results with molecular investigation and shown their usefulness as predictive factors for determination of Microsatellite Instability in patients with colorectal carcinomas in routinely.
Methods:
Forty seven colorectal cancers and their adjacent colonic mucosa were selected retrospectively for this study. We first studied the potential value of molecular investigation to identify microsatellite instability in which a NCI panel (or Bethesda panel) of five microsatellite was analyzed (Bat-25, Bat-26, D2S123, D5S346 and D17S250). Secondary, we evaluated the immunohistochemical assessment of hMLH1, hMSH2, hMSH6 and PMS2 proteins in tumor and adjacent normal colorectal mucosa tissues.
Results:
Fourteen cases were scored as MSI and the remaining MSS. Moreover, we found loss of expression for hMLH1, hMSH2, hMSH6 and PMS2 respectively in 9, 10, 6 and 9 of cases. The MSI patients were less than 45 years old, have right localization and mucinous histological type. We found an association between MSH2, age (P=0.03) and staging (P=0.02). MLH1 is associated only with age (P=0.02) while MSH6 with tumor grade (P=0.01).
Conclusions:
We found an association between MSI molecular investigation and MMR immunohistochemical expression which may allow one to specifically identify MSI phenotype of patients with colorectal carcinomas. Furthermore, immunohistochemical analysis of MMR protein can be used in routinely for detection of microsatellite instability without occurs to molecular investigation.

Keywords:

Microsatellite instability, colorectal cancer, immunohistochemistry, MMR protein, Bethesda panel.

##plugins.themes.academic_pro.article.details##

References

  1. Kin C KE, Poultsides GA, Visser BC, Jeffrey SS.Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev Mol Diagn 2013;6:581-99.
  2. Siegel R ND, Jemal A. Cancer statistics. CA Cancer J Clin 2013;63(1):11-30.
  3. Dietmaier W WS, Bocker T, Kullmann F, Fishel R, Rüschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997;57:4749-56.
  4. JMD W. Epigenetic, mismatch repair genes and colorectal cancer. Ann R Coll Surg Engl 2005;87:15-20.
  5. Sang-Bong Jung H-IL, Hoon-Kyu Oh, Im-Hee Shin and Chang-ho Jeon. Clinico-pathologic parameters for prediction of microsatellite instability in colorectal cancer. Cancer Res treat 2012;44(3):179-86.
  6. Boland GM CG, Haynes AB, Chiang YJ, Chagpar R, Xing Y. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer Res. 2013;119(8):1593-601.
  7. M K. Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options. Pathologie. 2013;34:277-81.
  8. Ferlay J SH, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917.
  9. Mostert B JY, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, et al.. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 2013;133(1):130-41.
  10. Y N. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil. Isr Med Assoc J 2005;7(8):520-4.
  11. Hemminki A MJ, Järvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119(4):921-8.
  12. Elsaleh H IB. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001;1(2):104-9.
  13. Rodriguez-Bigas MA BC, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. . A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.
  14. Zhou XP HJ, Li YJ, Senuca R, Cameiro F, Sobrinhi-Simoes M, et al.. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Gene chromosomes cancer 1998;21(2):101-7.
  15. Mensenkamp AR VI, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, et al. . Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2013;146(3):643-6.
  16. Aissi S BM, Zerimech F, Kourda N, Moussa A, Manai M, et al. . Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia. World J Gastroenterol 2013;19(32):5286-94.
  17. Marra G JJ. DNA mismatch repair and colon cancer. Adv Exp Med Biol 2005;570:85-123.
  18. Edmonston TB CK, Burkholder S, Barusevicius A, Rose D, Kovatich AJ, et al. Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers. Hum Pathol 2000;31(12):1506-14.
  19. Rigau V NSB, Sylviane O, Francois P, NajatM, Yann P, et al. . Microsatellite instability in colorectal carcinoma: the comparison of immunohistochemistry and molecular biology suggests a role for hMLH6 immunostaining. Arch Pathol Lab Med 2003;127:694-700.
  20. Roth AD D, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. . Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104(21):1635-46.
  21. Kang BW KJ, Lee SJ, Chae YS, Moon JH, Sohn SK, et al.. Clinical significance of microsatellite instability for stage II or III colorectal cancer following adjuvant therapy with doxifluridine. Med Oncol 2011;28(1):214-8.
  22. Malhotra P AM, Kochhar R, Ahmad S, Vaiphei K, Mahmood S. Promoter methylation and immunohistochemical expression of hMLH1 and hMSH2 in sporadic colorectal cancer: a study from India. Tumor Biol 2014;35(4):3679-87.
  23. Suraweera N DA, Reperant M, Vaury C, Furlan D, Leroy K, et al. . Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002;123:1804-11.
  24. Lech G SR, Krasnodebski IW The role of tumor markers and biomarkers in colorectal cancer. Neoplasma 2014;61(1):1-8.
  25. Patil DT BM, Portier BP, Fraser CR, Plesec TP, Liu X. A five-marker panel in a multiplex PCR accurately detects microsatellite instability-high colorectal tumors without control DNA. Diagn Mol Pathol 2012;21(3):127-33.
  26. Lawes DA PT, SenGupta S, Boulos PB. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Br J Cancer 2005;93:472-7.
  27. Lanza G GR, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol 2002;15(7):741-9.
  28. Jung KW PS, Won YJ, Kong HJ, Lee JY, Park EC, et al. . Prediction of cancer incidence and mortality in Korea.Cancer Res Treat 2011;43:12-8.